肽類抗生素市場規模、佔有率和成長分析：按類型、原料、適應症、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

2024 年全球胜肽類抗生素市場價值為 35.2 億美元，預計到 2033 年將從 2025 年的 37.7 億美元成長至 65.2 億美元，預測期（2026-2033 年）的複合年成長率為 7.12%。

全球胜肽類抗生素市場受到日益嚴峻的抗菌素抗藥性挑戰的顯著影響，亟需突破傳統小分子藥物的限制，尋找對多重抗藥性病原體療效欠佳的創新解決方案。該市場涵蓋天然來源和合成的治療性胜肽，因其獨特的作用機制和較低的交叉抗藥性風險而備受關注。胜肽合成和生物技術的進步正在提升其臨床應用潛力，並加速向工程化化合物的轉化。關鍵的成長要素包括改進的合成方法，這些方法能夠降低生產成本、提高穩定性並擴大商業應用範圍。此外，人工智慧的進步正在簡化藥物發現和開發流程，最佳化先導化合物的選擇，減少實驗迭代次數，從而提高效率和投資吸引力，尤其是在新興市場。

全球肽類抗生素市場的成長要素

全球肽類抗生素市場的主要促進因素之一是抗生素抗藥性細菌病菌感染的日益增加。隨著傳統抗生素療效的下降，醫療專業人員正轉向使用胜肽類抗生素作為替代治療方法，因為它們具有獨特的作用機制和對抗藥性細菌的高效性。此外，胜肽類抗生素通常比傳統抗生素毒性更低，且適用於更廣泛的患者群體。這種治療模式的轉變，以及人們對對抗抗菌素抗藥性創新解決方案需求的日益重視，正在推動各種醫療機構對胜肽類抗生素的需求不斷成長。

全球胜肽類抗生素市場面臨的限制因素

全球肽類抗生素市場的主要限制因素之一是抗生素抗藥性的蔓延，這限制了現有肽類抗生素的療效。隨著細菌的進化和抗藥性機制的產生，這些療法的有效性降低，導致治療失敗和醫療成本增加。這一日益嚴重的問題促使監管機構和醫療專業人員優先考慮其他方法，例如開發新型抗生素和加強預防措施，這可能會阻礙胜肽類抗生素的發展。此外，高昂的研發成本以及嚴格的監管核准流程也進一步阻礙了市場擴張和創新。

全球胜肽類抗生素市場趨勢

全球胜肽類抗生素市場正經歷著向標靶治療創新方向的強勁轉變，這主要得益於人們對序列特異性設計和智慧結合策略日益成長的關注。這一趨勢旨在提高對抗藥性病原體的選擇性，同時最大限度地減少對有益微生物群的影響。模組化化學、載體胜肽和製劑技術的持續進步，透過實現個人化的藥物動力學特徵和門診給藥，進一步吸引了精準醫療主導的投資。這些趨勢正在加速產品線的差異化，並促進藥物化學和臨床研究領域的合作。這推動了具有明確臨床價值和競爭優勢的靶向作用機制的藥物的開發，使其優於傳統的頻譜抗生素。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球胜肽類抗生素市場規模：按類型分類

• 環肽類抗生素（多粘菌素）
• Daptomycin
• 線性胜肽類抗生素
• 醣肽（萬古黴素）

全球胜肽類抗生素市場規模：依來源分類

• 天然的（源自微生物的）
• 合成/半合成

全球胜肽類抗生素市場規模：依適應症分類

• 抗甲氧西林金黃色葡萄球菌及革蘭氏陽性病菌感染
• 革蘭氏陰性病菌感染
• 黴菌感染疾病

全球胜肽類抗生素市場規模：依給藥途徑分類

• 靜脈注射/注射藥物
• 口服

全球胜肽類抗生素市場規模：依最終用戶分類

• 醫院
• 專科診所

全球胜肽類抗生素市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• GlaxoSmithKline
• Merck & Co.
• Eli Lilly
• AstraZeneca
• Melinta Therapeutics
• Paratek Pharmaceuticals
• Iterum Therapeutics
• Achaogen（dissolved）
• Theravance Biopharma
• Macrolide Pharmaceuticals
• Tetraphase Biosciences
• Allecra Therapeutics
• Shionogi & Co.
• Basilea Pharmaceutica
• Entasis Therapeutics
• Nabriva Therapeutics
• Spero Therapeutics
• QPex Biopharma
• Venatorx Pharmaceuticals

結論與建議

Global Peptide Antibiotics Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 3.77 Billion in 2025 to USD 6.52 Billion by 2033, growing at a CAGR of 7.12% during the forecast period (2026-2033).

The global peptide antibiotics market is significantly influenced by the rising challenge of antimicrobial resistance, necessitating innovative solutions beyond traditional small-molecule drugs ineffective against multidrug-resistant pathogens. The market encompasses therapeutic peptides, both naturally derived and synthetic, which are increasingly favored due to their unique action mechanisms and lower risk of cross-resistance. The sector is witnessing a transition towards engineered compounds, facilitated by advances in peptide synthesis and biotechnology that enhance their clinical potential. Key growth drivers include improved synthesis methods that lower production costs and boost stability, enabling wider commercial use. Alongside, AI advancements streamline the discovery and development process, optimizing lead candidate selection and reducing experimental iterations, thus enhancing efficiencies and investment appeal, particularly in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Peptide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Peptide Antibiotics Market Segments Analysis

Global peptide antibiotics market is segmented by type, source, indication, route, end-user and region. Based on type, the market is segmented into Cyclic Peptide Antibiotics (Polymyxin, Daptomycin), Linear Peptide Antibiotics and Glycopeptides (Vancomycin). Based on source, the market is segmented into Natural (Microbial-Derived) and Synthetic/Semi-Synthetic. Based on indication, the market is segmented into MRSA & Gram-Positive Infections, Gram-Negative Infections and Fungal Infections. Based on route, the market is segmented into IV/Injectable and Oral. Based on end-user, the market is segmented into Hospitals and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Peptide Antibiotics Market

One of the key market drivers for the Global Peptide Antibiotics Market is the rising incidence of antibiotic-resistant bacterial infections. As conventional antibiotic treatments become increasingly ineffective, healthcare providers are turning to peptide antibiotics as alternative therapeutic options due to their unique mechanisms of action and potency against resistant strains. Furthermore, peptide antibiotics often exhibit lower toxicity compared to traditional antibiotics, making them suitable for a wider range of patients. This shift in treatment paradigms, compounded by the growing awareness of the need for innovative solutions in combating antimicrobial resistance, is propelling the demand for peptide antibiotics across various healthcare settings.

Restraints in the Global Peptide Antibiotics Market

One key market restraint for the global peptide antibiotics market is the rising prevalence of antibiotic resistance, which limits the efficacy of existing peptide antibiotics. As bacteria evolve and develop resistance mechanisms, the effectiveness of these therapeutic agents diminishes, leading to treatment failures and increased healthcare costs. This growing concern prompts regulatory bodies and healthcare providers to prioritize alternative approaches, such as developing novel antibiotics or enhancing preventive measures, which may impede the growth of peptide antibiotics. Additionally, the high costs associated with research and development, alongside stringent regulatory approvals, further challenge the market's expansion and innovation.

Market Trends of the Global Peptide Antibiotics Market

The Global Peptide Antibiotics market is evidencing a robust shift towards innovation in targeted therapeutics, driven by a growing emphasis on sequence-specific designs and smart conjugation strategies. This trend aims to enhance selectivity against resistant pathogens while minimizing effects on beneficial microbiota. Ongoing advancements in modular chemistries, carrier peptides, and formulation techniques are facilitating personalized pharmacokinetic profiles and enabling outpatient administration, further attracting precision-driven investments. Such dynamics foster deeper pipeline differentiation, instigating collaborations across medicinal chemistry and clinical research sectors to develop focused mechanisms that present distinct clinical value and competitive positioning compared to traditional broad-spectrum antibiotics.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Peptide Antibiotics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Cyclic Peptide Antibiotics (Polymyxin)
• Daptomycin
• Linear Peptide Antibiotics
• Glycopeptides (Vancomycin)

Global Peptide Antibiotics Market Size by Source & CAGR (2026-2033)

• Market Overview
• Natural (Microbial-Derived)
• Synthetic/Semi-Synthetic

Global Peptide Antibiotics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• MRSA & Gram-Positive Infections
• Gram-Negative Infections
• Fungal Infections

Global Peptide Antibiotics Market Size by Route & CAGR (2026-2033)

• Market Overview
• IV/Injectable
• Oral

Global Peptide Antibiotics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics

Global Peptide Antibiotics Market Size & CAGR (2026-2033)

• North America (Type, Source, Indication, Route, End-User)
  • US
  • Canada
• Europe (Type, Source, Indication, Route, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Source, Indication, Route, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Source, Indication, Route, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Source, Indication, Route, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Melinta Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Paratek Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iterum Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Achaogen (dissolved)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrolide Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tetraphase Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allecra Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Basilea Pharmaceutica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entasis Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spero Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QPex Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Venatorx Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations